Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Completed · Not applicable

Conditions studied: Gastrointestinal Cancer, Nausea Post Chemotherapy

In brief

This clinical trial studies fosaprepitant dimeglumine in preventing nausea and vomiting in patients with gastrointestinal cancer receiving combination chemotherapy. Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.

Key facts

Study ID

NCT01504711

Run by

Philip Philip

People needed

30

Starts

2012-06-01

Expected to finish

2020-09-03

Last updated by the study team

2021-04-08

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient receiving FOLFIRINOX chemotherapy
• Southwest Oncology Group (SWOG) Performance status 0 or 1
• Ability of patient or guardian to understand and to provide voluntary written informed consent

You may not qualify if…

• Patient with current illness requiring chronic systemic steroids use or requiring chronic use of anti emetics
• Patients with gastrointestinal (GI) obstruction or active peptic ulcer disease who cannot take oral medication
• Known hypersensitivity to any component of the study regimen
• Patients taking any of the following medications: Oral contraceptives (except for the administration of stopping menses), tolbutamide, phenytoin, midazolam, ketoconazole, rifampin, paroxetine, and Diltiazem
• Pregnant or nursing women
• Patients using illegal drugs

Where it is running

• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.